CN118001622B - Normal tissue protection device for BNCT (brain-based cancer therapy) treatment of lung cancer - Google Patents
Normal tissue protection device for BNCT (brain-based cancer therapy) treatment of lung cancer Download PDFInfo
- Publication number
- CN118001622B CN118001622B CN202410412496.7A CN202410412496A CN118001622B CN 118001622 B CN118001622 B CN 118001622B CN 202410412496 A CN202410412496 A CN 202410412496A CN 118001622 B CN118001622 B CN 118001622B
- Authority
- CN
- China
- Prior art keywords
- boron
- containing polyethylene
- plate
- normal tissue
- protection device
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010058467 Lung neoplasm malignant Diseases 0.000 title claims abstract description 13
- 201000005202 lung cancer Diseases 0.000 title claims abstract description 13
- 208000020816 lung neoplasm Diseases 0.000 title claims abstract description 13
- 210000004556 brain Anatomy 0.000 title description 2
- 238000011275 oncology therapy Methods 0.000 title description 2
- 239000004698 Polyethylene Substances 0.000 claims abstract description 76
- -1 polyethylene Polymers 0.000 claims abstract description 76
- 229920000573 polyethylene Polymers 0.000 claims abstract description 76
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims abstract description 69
- 229910052796 boron Inorganic materials 0.000 claims abstract description 69
- 238000007493 shaping process Methods 0.000 claims abstract description 21
- 229910052580 B4C Inorganic materials 0.000 claims abstract description 15
- INAHAJYZKVIDIZ-UHFFFAOYSA-N boron carbide Chemical compound B12B3B4C32B41 INAHAJYZKVIDIZ-UHFFFAOYSA-N 0.000 claims abstract description 15
- 230000000694 effects Effects 0.000 abstract description 14
- 238000000034 method Methods 0.000 abstract description 4
- 210000004072 lung Anatomy 0.000 description 25
- 206010028980 Neoplasm Diseases 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 6
- 230000005855 radiation Effects 0.000 description 6
- 231100000987 absorbed dose Toxicity 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005192 partition Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 238000009434 installation Methods 0.000 description 2
- PQXKHYXIUOZZFA-UHFFFAOYSA-M lithium fluoride Chemical compound [Li+].[F-] PQXKHYXIUOZZFA-UHFFFAOYSA-M 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000000614 rib Anatomy 0.000 description 2
- 230000011218 segmentation Effects 0.000 description 2
- 238000010146 3D printing Methods 0.000 description 1
- 230000037237 body shape Effects 0.000 description 1
- 230000005880 cancer cell killing Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- YAFKGUAJYKXPDI-UHFFFAOYSA-J lead tetrafluoride Chemical compound F[Pb](F)(F)F YAFKGUAJYKXPDI-UHFFFAOYSA-J 0.000 description 1
- ORUIBWPALBXDOA-UHFFFAOYSA-L magnesium fluoride Chemical compound [F-].[F-].[Mg+2] ORUIBWPALBXDOA-UHFFFAOYSA-L 0.000 description 1
- 229910001635 magnesium fluoride Inorganic materials 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000002720 stereotactic body radiation therapy Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K3/00—Use of inorganic substances as compounding ingredients
- C08K3/38—Boron-containing compounds
-
- G—PHYSICS
- G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
- G21F—PROTECTION AGAINST X-RADIATION, GAMMA RADIATION, CORPUSCULAR RADIATION OR PARTICLE BOMBARDMENT; TREATING RADIOACTIVELY CONTAMINATED MATERIAL; DECONTAMINATION ARRANGEMENTS THEREFOR
- G21F1/00—Shielding characterised by the composition of the materials
- G21F1/02—Selection of uniform shielding materials
- G21F1/08—Metals; Alloys; Cermets, i.e. sintered mixtures of ceramics and metals
- G21F1/085—Heavy metals or alloys
-
- G—PHYSICS
- G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
- G21F—PROTECTION AGAINST X-RADIATION, GAMMA RADIATION, CORPUSCULAR RADIATION OR PARTICLE BOMBARDMENT; TREATING RADIOACTIVELY CONTAMINATED MATERIAL; DECONTAMINATION ARRANGEMENTS THEREFOR
- G21F3/00—Shielding characterised by its physical form, e.g. granules, or shape of the material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
- A61N2005/1094—Shielding, protecting against radiation
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- High Energy & Nuclear Physics (AREA)
- General Engineering & Computer Science (AREA)
- Metallurgy (AREA)
- Organic Chemistry (AREA)
- Radiology & Medical Imaging (AREA)
- Polymers & Plastics (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ceramic Engineering (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Radiation-Therapy Devices (AREA)
Abstract
The invention relates to the technical field of medical treatment, and particularly discloses a normal tissue protection device for treating lung cancer by BNCT, wherein the normal tissue protection device is arranged at an outflow opening of a beam shaping body and comprises a boron-containing polyethylene plate and a lead plate which are mutually attached, and the boron-containing polyethylene plate is provided with a beam outlet which is matched with the position and the size of the outflow opening; the total thickness of the boron-containing polyethylene plate and the lead plate is 3 cm-5 cm; the boron-containing polyethylene plate is formed by mixing and pressing boron carbide and polyethylene, the content of the boron carbide is 19% -26%, the content of the polyethylene is 74% -81%, and the purity of the lead plate is more than 99%. The normal tissue protection device can effectively protect normal tissues of a patient from being damaged by scattered neutron beams and gamma rays and from being damaged by irradiation; the shielding effect is ensured without direct contact with a patient, and the comfort of the patient is better; and moreover, the method is not required to be tailored according to the body type difference of the patient, so that the universality is strong, and the cost is remarkably reduced.
Description
Technical Field
The invention relates to the technical field of medical treatment, in particular to a normal tissue protection device for treating lung cancer by BNCT.
Background
Boron Neutron Capture Therapy (BNCT) has the property of binary targeting, and as the boron-containing compound is selectively accumulated in cells of cancer tissues, the following reaction is initiated on the cell scale by irradiation of low-energy neutron beams on the cancer tissues: 10B+n→α+7 Li+0.478MeV, thereby realizing targeted killing of cancer cells. However, since the boron drug is inevitably distributed in the normal tissue, and there is a certain degree of scattering of the neutron beam flow added to the beam outlet, the absorbed dose of the normal tissue needs to be evaluated before the BNCT treatment, and if the dose exceeds the standard, the normal tissue needs to be protected.
According to guidelines in the national integrated cancer network (NCCN) report, there are three irradiation modalities for lung cancer treatment, 1 partition 34Gy,3 partitions 60Gy and 5 partitions 55Gy, respectively. From Meng Ka calculations, it was found that in the 1-fraction 34Gy irradiation protocol, as shown in fig. 9, none of the healthy organs near the tumor, including skin, whole lung, ribs, heart, liver, esophagus exceeded the dose limits prescribed in the american society of medical and physical agents (AAPM). In the 5-fraction 55Gy irradiation protocol, as shown in fig. 11, healthy organs near the tumor, including skin, whole lung, ribs, heart, liver, esophagus, did not exceed the dose limit specified in the american medical physicist AAPM report "Stereotactic body radiation therapy: the report of AAPM Task Group 101". However, in the 3-fraction 60Gy irradiation protocol, as shown in fig. 10, the lung healthy tissue dose exceeds the dose limit and the irradiation dose of the remaining healthy tissue is higher, with the risk of exceeding the threshold.
The traditional radiation shielding scheme is that the shielding clothes made of wearable flexible materials are worn on a patient to cover non-irradiated parts, so that the normal tissues are protected. However, this shielding method has a disadvantage in that the difference in body type among patients is large, and the versatility of the shielding clothes is poor; if the ordering is performed according to the body shape of the patient, the time is longer and the cost is higher; in addition, the shielding clothes are flexible, but have heavy weight, so that the wearing comfort is poor, and the radiation treatment time is long, so that the comfort in the treatment process of a patient is poor.
In addition, in the prior art, there is a radiation shielding scheme, for example, a radiation shielding device based on medical image disclosed in chinese patent publication No. CN206535012U, which collects body type data of a patient based on medical scanning, performs data processing and builds a three-dimensional model, and obtains a customized shielding body through 3D printing.
Disclosure of Invention
The invention aims to solve the technical problem of providing the normal tissue protection device for treating lung cancer by BNCT, which can effectively protect normal tissues of a patient from being damaged by scattered neutron beams and gamma rays in an irradiation scheme based on 3-time segmentation of 60Gy and has the technical advantages of strong universality, good comfort and low cost.
In order to solve the technical problems, the technical scheme provided by the invention is as follows: a normal tissue protection device for treating lung cancer by BNCT, wherein the normal tissue protection device is configured at a beam outlet of a beam shaping body, the normal tissue protection device comprises a boron-containing polyethylene plate and a lead plate which are mutually attached, the boron-containing polyethylene plate is positioned at one side close to the beam shaping body, and the lead plate is positioned at one side far away from the beam shaping body; the boron-containing polyethylene plate is provided with beam outlet holes which are matched with the positions and the sizes of the beam outlets, and the positions of the lead plate corresponding to the beam outlet holes are not provided with beam outlet holes so as to be kept complete; the total thickness of the boron-containing polyethylene plate and the lead plate is 3 cm-5 cm; the boron-containing polyethylene plate is formed by mixing and pressing boron carbide and polyethylene, wherein the content of the boron carbide is 19% -26%, the content of the polyethylene is 74% -81%, and the purity of the lead plate is more than 99%.
In the normal tissue protection device with the structure, in the irradiation scheme based on 60Gy of 3-time segmentation when BNCT is used for treating lung cancer, the boron-containing polyethylene plate is used for shielding the scattering of neutron beams, and the lead plate is used for shielding gamma rays, so that the normal tissue of a patient can be effectively protected from being damaged by the scattered neutron beams and gamma rays, and the radiation dose received by normal organs near the lung is below a limit value and is prevented from being damaged by irradiation.
The normal tissue protection device with the structure is arranged at the beam outlet of the beam shaping body, does not need to be in direct contact with a patient, and has better comfort for the patient while ensuring the shielding effect; in addition, the method is not required to be ordered according to the body type difference of the patient, the universality is strong, the cost is obviously reduced, and the economic burden of the patient is smaller.
In a preferred embodiment, the total thickness of the boron-containing polyethylene sheet and lead sheet is 3cm.
In a preferred embodiment, the thickness of the boron-containing polyethylene plate is 2 cm-2.5 cm, and the thickness of the lead plate is 1 cm-0.5 cm.
In a preferred embodiment, the thickness of the boron-containing polyethylene plate is 2cm and the thickness of the lead plate is 1cm.
In a preferred embodiment, the thickness of the boron-containing polyethylene plate is 2.5cm and the thickness of the lead plate is 0.5cm.
In a preferred embodiment, the boron carbide content is 20% and the polyethylene content is 80%.
In a preferred embodiment, the boron-containing polyethylene plate is attached to the outer wall of the beam shaping body.
In a preferred embodiment, the normal tissue protection device is detachably mated with the beam shaping body.
The normal tissue protection device with the structure is detachably matched with the beam shaping body, so that the normal tissue protection device can be conveniently replaced, and the proper normal tissue protection device can be replaced according to the cancer type, focus position and the like of a patient, and the application range is wider.
Drawings
FIG. 1 is a schematic view of a beam shaping body in a BNCT therapeutic apparatus according to the present embodiment;
FIG. 2 is a schematic diagram showing the positional relationship among the normal tissue protection device, the beam shaping body and the patient in the BNCT treatment of lung cancer according to the present embodiment;
FIG. 3 is a schematic diagram showing an explosion state structure of the normal tissue protection device according to the present embodiment;
FIG. 4 is a graph showing the effect of thickness variation of the boron-containing polyethylene sheet on total lung dose and treatment time in the case where the total thickness of the boron-containing polyethylene sheet and lead sheet in this example is 2 cm;
FIG. 5 is a graph showing the effect of thickness variation of the boron-containing polyethylene sheet on total lung dose and treatment time in the case where the total thickness of the boron-containing polyethylene sheet and lead sheet in this example is 3 cm;
FIG. 6 is a graph showing the effect of thickness variation of the boron-containing polyethylene sheet on total lung dose and treatment time in the case where the total thickness of the boron-containing polyethylene sheet and lead sheet in this example is 4 cm;
FIG. 7 is a graph showing the effect of thickness variation of the boron-containing polyethylene sheet on total lung dose and treatment time in the case where the total thickness of the boron-containing polyethylene sheet and lead sheet in this example is 5 cm;
FIG. 8 is a graph showing the effect of boron carbide content variation in a boron-containing polyethylene sheet on total lung dose at a thickness combination of 2.5cm+0.5cm for a boron-containing polyethylene sheet and a lead sheet;
FIG. 9 is a graph of total dose absorbed by each organ versus dose limit for a1 fraction 34Gy irradiation protocol;
FIG. 10 is a graph of total dose absorbed by each organ versus dose limit for a 3 fraction 60Gy irradiation protocol;
FIG. 11 is a graph of total dose absorbed by each organ versus dose limit for a 5 fraction 55Gy irradiation protocol.
Detailed Description
The present invention will be described in further detail with reference to the drawings and examples, in order to make the objects, technical solutions and advantages of the present invention more apparent. It should be understood that the specific embodiments described herein are for purposes of illustration only and are not intended to limit the scope of the invention.
In the description of the present invention, it should be understood that the directions or positional relationships indicated by the terms "upper", "lower", "front", "rear", "inner", "outer", etc., are based on the directions or positional relationships shown in the drawings, are merely for convenience of describing the present invention and simplifying the description, and do not indicate or imply that the devices or elements referred to must have a specific orientation, be constructed and operated in a specific orientation, and thus should not be construed as limiting the present invention.
In the description of the present invention, it should be noted that, unless explicitly specified and limited otherwise, the terms "mounted," "connected," and "connected" are to be construed broadly, and may be, for example, fixedly connected, integrally connected, or detachably connected; may be a communication between the interiors of two elements; may be directly or indirectly through an intermediate medium, and the specific meaning of the terms in the present invention will be understood by those skilled in the art in specific cases.
As shown in fig. 1, the beam shaper 10 of the BNCT based on the accelerator comprises materials such as magnesium fluoride, lead and lithium fluoride, which slow down neutrons with higher energy generated by a neutron target into neutron beams mainly comprising epithermal neutrons and suitable for cancer treatment, and the neutron beams are emitted from the beam outlet 11. There is a proportion of the scattered neutron beam passing through the beam shaper 10, which would impinge on healthy tissue of the patient and create radiation damage.
In order to protect the normal tissue dose of the patient from exceeding the dose limit (total lung dose less than 3.1 Gy) prescribed in AAPM of the american society of medical physics and physical arts during the treatment of lung cancer by BNCT, the present embodiment provides a normal tissue protecting device 20 for the treatment of lung cancer by BNCT, wherein the normal tissue protecting device 20 is disposed at the beam outlet 11 of the beam shaper 10, as shown in fig. 2, between the beam shaper 10 and the patient 30.
As shown in fig. 2 and 3, the normal tissue protection device 20 in this embodiment includes a boron-containing polyethylene plate 21 and a lead plate 22 that are attached to each other, wherein the boron-containing polyethylene plate 21 is located on a side close to the beam shaping body 10, and the lead plate 22 is located on a side far from the beam shaping body 10. Wherein a boron-containing polyethylene plate 21 is used for shielding the scattering of neutron beams, and a lead plate 22 is used for shielding gamma rays.
In this embodiment, the boron-containing polyethylene plate 21 is provided with a beam outlet hole 23 adapted to the position and size of the beam outlet 11, so that the neutron beam irradiates the focal zone of the patient smoothly, and the lead plate 22 has a small attenuation effect on the neutron and is mainly used for shielding gamma rays, so that the position of the lead plate 22 corresponding to the beam outlet hole 23 is not provided with a beam outlet hole, and thus remains intact.
In this embodiment, the boron-containing polyethylene plate 21 is formed by mixing and pressing boron carbide and polyethylene, and the purity of the lead plate 22 is 99% or more.
In this embodiment, the total thickness of the boron-containing polyethylene plate 21 and the lead plate 22 may be 3cm to 5cm, and the total thickness of the normal tissue protection device 20 is set to 2cm, 3cm, 4cm and 5cm, respectively, and the effect on the total lung dose and the treatment time is verified by the thickness variation of the boron-containing polyethylene plate 21.
In the case where the total thickness of the boron-containing polyethylene sheet 21 and the lead sheet 22 is 2cm, fig. 4 illustrates the effect of the thickness variation of the boron-containing polyethylene sheet 21 on the total lung dose and the treatment time, and it is seen that the total lung dose is always higher than the dose limit value of 3.1Gy, and the normal tissue protection device 20 having the total thickness of 2cm cannot meet the requirement.
In fig. 5, the effect of the thickness variation of the boron-containing polyethylene plate 21 on the total lung dose and the treatment time is shown by the example of the total thickness of the boron-containing polyethylene plate 21 and the lead plate 22 being 3cm, and it is seen that when the thicknesses of the boron-containing polyethylene plate 21 and the lead plate 22 are respectively 2cm to 2.5cm and 1cm to 0.5cm, the total lung dose is lower than the dose limit value of 3.1Gy, so that the shielding requirement can be satisfied, and the corresponding treatment time is 73min to 78min.
In fig. 6, the effect of the thickness variation of the boron-containing polyethylene sheet 21 on the total lung dose and the treatment time is shown in the case that the total thickness of the boron-containing polyethylene sheet 21 and the lead sheet 22 is 4cm, and it can be seen that when the thicknesses of the boron-containing polyethylene sheet 21 and the lead sheet 22 are respectively 2.5cm to 3.3cm and 1.5cm to 0.7cm, the total lung dose is lower than the dose limit value of 3.1Gy, so that the shielding requirement can be satisfied, and the corresponding treatment time is 73min to 80min.
In fig. 7, the effect of the thickness variation of the boron-containing polyethylene plate 21 on the total lung dose and the treatment time is shown in the case that the total thickness of the boron-containing polyethylene plate 21 and the lead plate 22 is 5cm, and it can be seen that when the thicknesses of the boron-containing polyethylene plate 21 and the lead plate 22 are respectively 2.8cm to 4.5cm and 2.2cm to 0.5cm, the total lung dose is lower than the dose limit value of 3.1Gy, so that the shielding requirement can be satisfied, and the corresponding treatment time is 68min to 82min.
As described above, meng Kaji shows that when the total thickness of the normal tissue protection device is increased uniformly from 3cm to 5cm, the number of combinations that result in a total lung dose below the dose limit is increased gradually and the corresponding treatment time is decreased continuously for each total thickness. The patient must remain in a fixed position during treatment, so the treatment time should be as short as possible, taking into account the comfort and the bearing capacity of the patient. In addition, it should be considered that the absorbed dose of healthy organs such as skin is below the dose limit when the total lung dose is below the limit. So under the comprehensive consideration of treatment time and absorbed dose, when the thickness combination of the boron-containing polyethylene plate 21 and the lead plate 22 is respectively 2cm+1cm and 2.5cm+0.5cm, the total lung dose is lower than 3.1Gy, and the treatment time is moderate, which belongs to the preferable thickness combination scheme.
In this embodiment, in the boron-containing polyethylene sheet 21, the content of boron carbide is 19% -26%, and the content of polyethylene is 74% -81%. Taking the example of the combination of the thickness of the boron-containing polyethylene sheet 21 and the lead sheet 22 of 2.5cm+0.5cm, the effect of the boron carbide content variation in the boron-containing polyethylene sheet 21 on the total lung dose and treatment time is shown in fig. 8. As shown in FIG. 8, when the boron carbide content is 19% -26%, the total lung dose is lower than the dose limit value by 3.1Gy, and the shielding requirement can be met. Preferably, the total lung dose is lowest when the boron carbide content is 20%.
In summary, in the normal tissue protection device 20 for treating lung cancer according to the present embodiment, in the irradiation scheme based on the 3-time division of 60Gy, the thickness combination of the boron-containing polyethylene plate 21 and the lead plate 22 is preferably 2.5cm+0.5cm, the boron carbide content in the boron-containing polyethylene plate 21 is 20%, and the polyethylene content is 80%.
Preferably, in this embodiment, the boron-containing polyethylene plate 21 is attached to the outer wall of the beam shaping body 10 without leaving a gap therebetween.
It should be noted that the normal tissue protection device 20 of the present embodiment may be fixedly disposed on the outer wall of the beam shaping body 10, but this way the function of the boron neutron capture treatment system becomes single. Preferably, the normal tissue protection device 20 and the beam shaping body 10 can be arranged in a detachable matching relationship, so that the normal tissue protection device 20 can be conveniently replaced, and the application range of the normal tissue protection device can be widened by selecting a shielding device with other materials, thickness and the like according to the cancer type, focus position and the like of a patient.
It should be emphasized that the relationship between the normal tissue protection device 20 and the beam shaping body 10 may be implemented by any technical means in the prior art, including but not limited to: the outer wall of the beam shaping body is provided with an installation position, and the normal tissue protection device is installed at the installation position in a detachable mode such as a bolt or a buckle; the normal tissue protection device is of an independent structure and is placed at a corresponding position when in use. In summary, the relationship of the separable mating between the normal tissue protection device 20 and the beam shaper 10 is not limited in the present application.
In summary, the foregoing description is only of the preferred embodiments of the invention, and is not intended to limit the invention to the particular embodiments disclosed, but on the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention.
Claims (6)
1. The normal tissue protection device for treating lung cancer by BNCT is characterized by being arranged at an outflow opening of a beam shaping body, and comprises a boron-containing polyethylene plate and a lead plate which are mutually attached, wherein the boron-containing polyethylene plate is positioned at one side close to the beam shaping body, and the lead plate is positioned at one side far away from the beam shaping body; the boron-containing polyethylene plate is provided with beam outlet holes which are matched with the positions and the sizes of the beam outlets, and the positions of the lead plate corresponding to the beam outlet holes are not provided with beam outlet holes so as to be kept complete; the total thickness of the boron-containing polyethylene plate and the lead plate is 3 cm-5 cm; the boron-containing polyethylene plate is formed by mixing and pressing boron carbide and polyethylene, wherein the content of the boron carbide is 19% -26%, the content of the polyethylene is 74% -81%, and the purity of the lead plate is more than 99%;
under the condition that the total thickness of the boron-containing polyethylene plate and the lead plate is 3cm, the thickness of the boron-containing polyethylene plate is 2 cm-2.5 cm, and the thickness of the lead plate is 1 cm-0.5 cm;
the thickness of the boron-containing polyethylene plate is 2.5 cm-3.3 cm, and the thickness of the lead plate is 1.5 cm-0.7 cm under the condition that the total thickness of the boron-containing polyethylene plate and the lead plate is 4 cm;
under the condition that the total thickness of the boron-containing polyethylene plate and the lead plate is 5cm, the thickness of the boron-containing polyethylene plate is 2.8 cm-4.5 cm, and the thickness of the lead plate is 2.2 cm-0.5 cm.
2. The normal tissue protection device of claim 1, wherein the thickness of the boron-containing polyethylene sheet is 2cm and the thickness of the lead sheet is 1cm, with the total thickness of the boron-containing polyethylene sheet and lead sheet being 3 cm.
3. The normal tissue protection device of claim 2, wherein the boron-containing polyethylene sheet has a thickness of 2.5cm and the lead sheet has a thickness of 0.5cm.
4. A normal tissue protection device according to claim 3, wherein the boron carbide content is 20% and the polyethylene content is 80%.
5. The normal tissue protection device of any one of claims 1-4, wherein the boron-containing polyethylene sheet is positioned in apposition to the outer wall of the beam shaping body.
6. The normal tissue protection device of claim 5, wherein the normal tissue protection device is detachably mated with the beam shaper.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410412496.7A CN118001622B (en) | 2024-04-08 | 2024-04-08 | Normal tissue protection device for BNCT (brain-based cancer therapy) treatment of lung cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410412496.7A CN118001622B (en) | 2024-04-08 | 2024-04-08 | Normal tissue protection device for BNCT (brain-based cancer therapy) treatment of lung cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN118001622A CN118001622A (en) | 2024-05-10 |
| CN118001622B true CN118001622B (en) | 2024-06-25 |
Family
ID=90947392
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410412496.7A Active CN118001622B (en) | 2024-04-08 | 2024-04-08 | Normal tissue protection device for BNCT (brain-based cancer therapy) treatment of lung cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN118001622B (en) |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1409263A (en) * | 1972-03-16 | 1975-10-08 | Elliott Brothers London Ltd | Neutron beam collimators |
| SU1762945A1 (en) * | 1990-03-23 | 1992-09-23 | Физико-энергетический институт | Device for remote neutron control therapy |
| JPH08201581A (en) * | 1995-01-30 | 1996-08-09 | Sutaaraito Kogyo Kk | Composition for radiation shield and its usage |
| RU2141860C1 (en) * | 1998-02-06 | 1999-11-27 | Ассоциация инвалидов радиационных катастроф и аварий "ИНРАД" | Method and device for treating malignant tumors by applying neutron-catching therapy |
| CN1151849C (en) * | 2000-11-09 | 2004-06-02 | 曾宪文 | Completely protected californium neutron cure machine |
| KR100889286B1 (en) * | 2005-02-25 | 2009-03-19 | 한국원자력연구원 | Polyethylene Shielding Material Containing Boron And Lead And Method For Preparing The Same |
| KR200406766Y1 (en) * | 2005-10-11 | 2006-01-24 | 김영창 | Scattered Radiation Attenuation Panel |
| CN201161341Y (en) * | 2007-11-30 | 2008-12-10 | 中国核动力研究设计院 | Fixture clamper for machine processing for manufacturing plumbum-boron polythene radiation protecting and shielding body |
| KR101217712B1 (en) * | 2010-12-20 | 2012-12-31 | 한국원자력연구원 | A prompt gamma-ray detection apparatus for analyzing chemical materials by using femto second pulse laser induced neutrons |
| CN104021831B (en) * | 2014-04-24 | 2016-11-09 | 中国人民解放军火箭军装备研究院第四研究所 | A kind of neutron radiation protective clothing package material |
| CN108066901B (en) * | 2016-11-14 | 2024-04-12 | 南京中硼联康医疗科技有限公司 | Radiation shielding device and method based on medical image |
| CN106808691B (en) * | 2017-02-15 | 2023-08-22 | 清华大学天津高端装备研究院 | Preparation system and preparation method of medical radiation protection equipment |
| KR20240093753A (en) * | 2021-10-27 | 2024-06-24 | 티에이이 라이프 사이언시스 엘엘씨 | Systems, devices and methods for converting neutron beams |
| JP2024000810A (en) * | 2022-06-21 | 2024-01-09 | 株式会社東芝 | Neutron and gamma-ray collimater, radiography device |
| CN115120895A (en) * | 2022-08-31 | 2022-09-30 | 兰州大学 | Neutron capture irradiation equipment |
| CN115300812A (en) * | 2022-08-31 | 2022-11-08 | 兰州大学 | Neutron beam grating irradiation system |
| CN115738100A (en) * | 2022-09-09 | 2023-03-07 | 合肥综合性国家科学中心能源研究院(安徽省能源实验室) | Boron Neutron Capture Therapy (BNCT) neutron moderation and beam shaping system |
-
2024
- 2024-04-08 CN CN202410412496.7A patent/CN118001622B/en active Active
Non-Patent Citations (2)
| Title |
|---|
| 曾自力 ; 陈默思 ; .肺癌肺内肿瘤三维适形放疗正常肺组织定义的研究.中国医学物理学杂志.2011,(01),全文. * |
| 李德安 ; 刘颖 ; 杨文锋 ; 杨林 ; 李军 ; 李梦 ; .新型铅基复合屏蔽材料组织结构与性能.材料导报.2006,(10),全文. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN118001622A (en) | 2024-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7464672B2 (en) | Beam shapers for neutron capture therapy. | |
| Sasaoka et al. | Dosimetric evaluation of whole breast radiotherapy using field-in-field technique in early-stage breast cancer | |
| EP3369457A1 (en) | Beam shaping body for neutron capture therapy | |
| EP1853346A2 (en) | Peripheral brachytherapy of protruding conformable organs | |
| CN204319539U (en) | For the beam-shaping body of neutron capture treatment | |
| CN118001622B (en) | Normal tissue protection device for BNCT (brain-based cancer therapy) treatment of lung cancer | |
| de Boer et al. | The effect of beam energy on the quality of IMRT plans for prostate conformal radiotherapy | |
| CN215275469U (en) | Novel breast cancer radiotherapy is fixed device | |
| CN207076025U (en) | Neutron capture therapeutic system | |
| Çakır et al. | Dosimetric comparison of 3D-conformal and IMRT radiotherapy techniques in gastric cancer | |
| Buckey et al. | Optimizing prostate intensity-modulated radiation therapy (IMRT): do stricter constraints produce better dosimetric results? | |
| Paliwal et al. | Attenuation characteristics of a new compensator material: Thermo‐Shield for high energy electron and photon beams | |
| CN213077253U (en) | Protective blanket for radiotherapy | |
| CN214485312U (en) | Novel tumor radiotherapy treatment bed | |
| Hajar et al. | An unusual case of nasopharyngial adenoid cystic carcinoma with intracranial and orbital extension: a challenge for innovative conformal radiotherapy techniques | |
| Lee et al. | Dosimetric comparison of four different external beams for breast irradiation | |
| Stewart | A wedge filter approach with 4 MV radiation to the treatment of carcinomata of the alveolus and antrum | |
| Alberti | Organ-confined prostate carcinoma radiation brachytherapy compared with external either photon-or hadron-beam radiation therapy. Just a short up-to-date. | |
| Moghaddam et al. | Boron Neutron Capture Therapy for Breast Cancer during Pregnancy: A Feasibility Study. | |
| CN108295385B (en) | Neutron capture therapeutic device | |
| Yoo et al. | Statistics for department of radiation oncology (1999~ 2001) | |
| ABBAS et al. | Asymmetric open field-in-field can replace wedged fields in tangential whole breast irradiation | |
| CN209451166U (en) | A kind of wearable tumor colli radiotheraphy device | |
| Lushnikova et al. | Modern Techniques for Cervical Cancer Radiotherapy | |
| CN117797417A (en) | neutron capture therapy system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |